Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...
A SCIENTIFIC panel created by the United Nations released its first independent assessment of artificial intelligence (AI) this month, and the warning at its center is a blunt one. The technology is ...
The U.S. Food and Drug Administration said on Friday it has approved a wearable form of Sanofi's blood cancer drug, ...
Polpharma Biologics will retain full responsibility for developing and manufacturing the biosimilar candidate.
Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy ...
Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026Presentation will highlight recent scientific advances and future opportunities ...
A four-month-old baby died at a Nottingham hospital after "omissions of care" prompted concerns from her bereaved parents.
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances T ...
Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances T ...
The biohacking therapy has attracted devotees from Bella Hadid to the Red Hot Chili Peppers. After more than a decade away, I ...
As a third-year internal medicine resident in 1988, I studied every person over 65 who entered our hospital emergency room ...
The FDA's Office of Prescription Drug Promotion issued an untitled letter to Lundbeck over claims on its webpages for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results